149 related articles for article (PubMed ID: 23433742)
21. Changing concepts in the management of endometrial cancer.
Karasek K; Faul C
Oncology (Williston Park); 1996 Jul; 10(7):1099-106, 1110; disc. 1112, 1115. PubMed ID: 8837124
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant treatment of advanced-stage endometrial cancer.
Lee NK
Clin Obstet Gynecol; 2011 Jun; 54(2):256-65. PubMed ID: 21508695
[TBL] [Abstract][Full Text] [Related]
23. Molecular target therapies in endometrial cancer: from the basic research to the clinic.
Gadducci A; Tana R; Cosio S; Fanucchi A; Genazzani AR
Gynecol Endocrinol; 2008 May; 24(5):239-49. PubMed ID: 18569027
[TBL] [Abstract][Full Text] [Related]
24. Molecular pathology of endometrial carcinoma.
Matias-Guiu X; Prat J
Histopathology; 2013 Jan; 62(1):111-23. PubMed ID: 23240673
[TBL] [Abstract][Full Text] [Related]
25. PTEN sensitizes epidermal growth factor-mediated proliferation in endometrial carcinoma cells.
Tang LL; Yokoyama Y; Wan X; Iwagaki S; Niwa K; Tamaya T
Oncol Rep; 2006 Apr; 15(4):855-9. PubMed ID: 16525671
[TBL] [Abstract][Full Text] [Related]
26. Biomarkers as prognostic factors in endometrial cancer.
Dobrzycka B; Terlikowski SJ
Folia Histochem Cytobiol; 2010 Sep; 48(3):319-22. PubMed ID: 21071332
[TBL] [Abstract][Full Text] [Related]
27. Treatment strategies for endometrial cancer: current practice and perspective.
Lee YC; Lheureux S; Oza AM
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):47-58. PubMed ID: 27941361
[TBL] [Abstract][Full Text] [Related]
28. Treatment modalities in endometrial cancer.
Amant F; Moerman P; Neven P; Timmerman D; Van Limbergen E; Vergote I
Curr Opin Oncol; 2007 Sep; 19(5):479-85. PubMed ID: 17762575
[TBL] [Abstract][Full Text] [Related]
29. Lymphadenectomy in women with endometrial cancer: aspiration and reality from a radiation oncologist's point of view.
Foerster R; Kluck R; Arians N; Rieken S; Rief H; Adeberg S; Bostel T; Schlampp I; Debus J; Lindel K
Radiat Oncol; 2015 Jul; 10():147. PubMed ID: 26179059
[TBL] [Abstract][Full Text] [Related]
30. [Molecular based targets and endometrial cancer].
Stoyanov S; Ananiev J; Ivanova K; Velev V; Todorova M; Gulubova M
Akush Ginekol (Sofiia); 2015; 54(2):38-45. PubMed ID: 25909140
[TBL] [Abstract][Full Text] [Related]
31. Endometrial carcinoma: a review of chemotherapy, drug resistance, and the search for new agents.
Moxley KM; McMeekin DS
Oncologist; 2010; 15(10):1026-33. PubMed ID: 20930101
[TBL] [Abstract][Full Text] [Related]
32. Update in the management of endometrial cancer.
Levine DA; Hoskins WJ
Cancer J; 2002; 8 Suppl 1():S31-40. PubMed ID: 12075700
[TBL] [Abstract][Full Text] [Related]
33. Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium.
Minaguchi T; Nakagawa S; Takazawa Y; Nei T; Horie K; Fujiwara T; Osuga Y; Yasugi T; Kugu K; Yano T; Yoshikawa H; Taketani Y
Cancer Lett; 2007 Apr; 248(1):112-22. PubMed ID: 16919866
[TBL] [Abstract][Full Text] [Related]
34. PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations.
Velasco A; Bussaglia E; Pallares J; Dolcet X; Llobet D; Encinas M; Llecha N; Palacios J; Prat J; Matias-Guiu X
Hum Pathol; 2006 Nov; 37(11):1465-72. PubMed ID: 16949921
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant treatment for endometrial cancer: literature review and recommendations by the Comité de l'évolution des pratiques en oncologie (CEPO).
Morneau M; Foster W; Lalancette M; Van Nguyen-Huynh T; Renaud MC; Samouëlian V; Letarte N; ; ; Almanric K; Boily G; Bouchard P; Boulanger J; Cournoyer G; Couture F; Gervais N; Goulet S; Guay MP; Kavanagh M; Lemieux J; Lespérance B; Letarte N; Morneau M; Ouellet JF; Pineau G; Rajan R; Roy I; Samson B; Sidéris L; Vincent F
Gynecol Oncol; 2013 Oct; 131(1):231-40. PubMed ID: 23872191
[TBL] [Abstract][Full Text] [Related]
36. Targeting the mTOR/4E-BP pathway in endometrial cancer.
Korets SB; Czok S; Blank SV; Curtin JP; Schneider RJ
Clin Cancer Res; 2011 Dec; 17(24):7518-28. PubMed ID: 22142830
[TBL] [Abstract][Full Text] [Related]
37. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
Bradford LS; Rauh-Hain A; Clark RM; Groeneweg JW; Zhang L; Borger D; Zukerberg LR; Growdon WB; Foster R; Rueda BR
Gynecol Oncol; 2014 May; 133(2):346-52. PubMed ID: 24561032
[TBL] [Abstract][Full Text] [Related]
38. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma.
Oda K; Stokoe D; Taketani Y; McCormick F
Cancer Res; 2005 Dec; 65(23):10669-73. PubMed ID: 16322209
[TBL] [Abstract][Full Text] [Related]
39. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
Ogawa K; Sun C; Horii A
Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
[TBL] [Abstract][Full Text] [Related]
40. Sentinel node biopsy for the management of early stage endometrial cancer: long-term results of the SENTI-ENDO study.
Daraï E; Dubernard G; Bats AS; Heitz D; Mathevet P; Marret H; Querleu D; Golfier F; Leblanc E; Rouzier R; Ballester M
Gynecol Oncol; 2015 Jan; 136(1):54-9. PubMed ID: 25450151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
